Virtual Symposium (CME Concluded): Addressing the Unmet Need of Diabetic Kidney Disease Progression: Beyond SGLT-2 Inhibitors and GLP-1 Ras

Diabetic kidney disease (DKD) is one of the most common complications of diabetes, affecting up to 50% of persons with diabetes, and leading to increased morbidity and mortality. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including mineralocorticoid receptor antagonism, which have the potential to improve outcomes for patients with DKD. In particular, non-steroidal mineralocorticoid receptor antagonists (MRAs) have shown promise in DKD, as demonstrated in recent clinical trial results, and several phase III trials are ongoing.

During this symposium, experts will discuss recent and emerging clinical trial data with MRAs in DKD, particularly non-steroidal MRAs. In addition, they will provide an overview about the underlying pathophysiology, how to identify patients at high-risk, and the current management of DKD.

Understanding the Pathophysiologic Link Between Cardiovascular Disease and Diabetic Kidney Disease

Presenter: George L. Bakris, MD

Management Options for Diabetes and DKD

Presenter: Ileana L. Piña, MD, MPH, FAHA, FACC

Emerging Targets and Therapeutic Options for DKD

Presenter: Rajiv Agarwal, MD

Case Presentation and Discussion

Presenter: George L. Bakris, MD

Panel: All Faculty

Audience Q&A

Panel: All Faculty